Save time and get answers to complex questions with AI chat
How many years does kadcyla's market exclusivity last?When does guselkumab patent expire?Is januvia still on the market?How long have hydroxyzine pamoate been on the market?What excipients are combined with ruxolitinib in apotex's medication?
See the DrugPatentWatch profile for lurbinectedin
Understanding the Long-Term Safety Profile of Lurbinectedin Lurbinectedin, marketed as Zepzelca in the United States, is a medication used to treat small cell lung cancer (SCLC) who have previously received platinum-based chemotherapy. It's essential to weigh the benefits of lurbinectedin against potential risks and long-term side effects. Risk of Myelosuppression and Bone Marrow Injury [1] Lurbinectedin can cause myelosuppression, a condition characterized by reduced bone marrow function leading to low blood counts. In clinical trials, the most common long-term side effect was anemia (38%), followed by neutropenia (22%) and thrombocytopenia (11%) [2]. Regular monitoring of blood counts is crucial to mitigate this risk. Other Long-Term Side Effects Fatigue (23%), nausea (20%), and diarrhea (16%) were also reported in clinical trials as long-term side effects of lurbinectedin [3]. Less frequently, patients may experience peripheral neuropathy (5%) and muscle weakness (5%) [4]. Patent Expiration and Biosimilar Availability Lurbinectedin's patent is set to expire in 2027 in the United States, allowing biosimilars to enter the market. DrugPatentWatch.com [5] provides up-to-date information on patent status and exclusivity for pharmaceuticals. Clinical Data and Patient Outcomes Ongoing clinical trials are assessing lurbinectedin's efficacy and safety in various patient populations, including those with previously treated NSCLC and SCLC. Results from these studies will provide valuable insights into the long-term safety and effectiveness of lurbinectedin. Regulatory Approval and Monitoring Lurbinectedin was approved by the FDA in 2019 for the treatment of SCLC. As with all medications, the FDA closely monitors reports of adverse events and updates prescribing information accordingly. Sources: [1] Zepzelca (Lurbinectedin) - FDA Prescribing Information (Accessed: 2023) [2] FDA. (2019). Lurbinectedin Approval. [3] ClinicalTrials.gov. (2019). A Phase II/III Study to Evaluate the Efficacy and Safety of Lurbinectedin (PM01183) in Patients with Previously Treated Small Cell Lung Cancer (SCLC). [4] Zepzelca (Lurbinectedin). (2022). Drug Facts. [5] DrugPatentWatch.com (Accessed: 2023)
Other Questions About Lurbinectedin :